肿瘤多药耐药:机制及逆转剂  

Tumor multidrug resistance: mechanism and reversal agents

作　　者：孙文霞[1] 黄才国[1] 

机构地区：[1]第二军医大学生物化学与分子生物学教研室,上海200433

出　　处：《生命的化学》2012年第5期395-399,共5页Chemistry of Life

基　　金：国家"973"项目(2010CB833804);国家"863"项目(2011AA09070110)资助

摘　　要：肿瘤细胞多药耐药性(multidrug resistance,MDR)的产生是临床上导致肿瘤化疗失败的主要原因之一,因此寻找高效低毒的MDR逆转剂已成为肿瘤药物开发领域的热点。MDR的作用机制主要包括P-糖蛋白、多药耐药相关蛋白、乳腺癌耐药蛋白、肺耐药相关蛋白等等。多药耐药逆转剂包括钙离子通道阻滞剂、维拉帕米及其衍生物等等。本文主要介绍了MDR的作用机制以及肿瘤多药耐药逆转剂的研究进展。Multidrug resistance （MDR） is one of the main obstacles limiting the efficacy of clinical chemotherapy treatment for tumors. Searching for highly effective and lowly toxic reversal agents for MDR is a hot field in regard to cancer drug development. The mechanisms of MDR mainly include P-glycoprotein, muhidrugresistance-associated protein, breast cancer resistance protein, lung resistant-related protein, etc.. MDR reversal agents include calcium channel blockers, Verapam and its derivative, etc.. This paper mainly introduces the mechanisms of MDR and the development of MDR reversal agents.

关 键 词：多药耐药 机制 逆转剂 

分 类 号：R730.5[医药卫生—肿瘤]